'Antibody Profiles and Genetics of Pernio-Like Lesions during the COVID-19 pandemic'
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3K23AI136579-03S1
Grant search
Key facts
Disease
COVID-19Start & end year
20212021Known Financial Commitments (USD)
$53,860Funder
National Institutes of Health (NIH)Principal Investigator
Esther E FreemanResearch Location
United States of AmericaLead Research Institution
Massachusetts General HospitalResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Project SummaryA subset of patients with coronavirus disease-2019 (COVID-19) develop cutaneous manifestations of theirsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including pernio of their feet andhands, known as "COVID toes." These patients tend to have a mild disease course, which may indicatesuccessful viral control by the host. By leveraging an existing patient cohort at Massachusetts General Hospital(MGH), and the extensive laboratory infrastructure at the NIH, this proposal aims to elucidate the complexdeterminants of a unique phenotype of COVID-19: pernio/ "COVID toes," with the following Aims. Aim 1: Toevaluate genetic determinants of pernio-like lesions ("COVID toes") in response to SARS-CoV-2 infection. Aim2: To characterize the inflammatory and serological response during acute infection and convalescence ofpatients with SARS-CoV-2 who develop pernio-like lesions as a symptom of COVID-19. Biological samples willbe obtained at MGH and sent to collaborating labs at the NIH. In particular, this proposal will help usunderstand the host immune response to COVID-19 by focusing on patients who have controlled the diseaseand have had relatively mild clinical courses, as characterized by their skin lesions. Successful completion ofour aims will immediately and directly respond to important gaps in our knowledge regardingmild/asymptomatic COVID-19, which in turn can help inform our understanding of how to harness this type ofsuccessful control for other patients.